revakinagene taroretcel

{{Short description|Medication}}

{{Use American English|date=March 2025}}

{{Use dmy dates|date=March 2025}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| image =

| width =

| alt =

| caption =

| gt_target_gene =

| gt_vector =

| gt_nucleic_acid_type =

| gt_editing_method =

| gt_delivery_method =

| pronounce =

| tradename = Encelto

| Drugs.com =

| MedlinePlus =

| DailyMedID = Revakinagene taroretcel

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = Intravitreal implantation

| class =

| ATC_prefix = None

| ATC_suffix =

| ATC_supplemental =

| biosimilars =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Encelto- revakinagene taroretcel-lwey implant | website=DailyMed | date=21 March 2025 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ae9482a-b478-4e21-9166-b5fd52d3ef9c | access-date=2 April 2025}}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number =

| CAS_supplemental =

| PubChem =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII = Q7V7NYG6GM

| UNII2 = J3LVA7RZT2

| KEGG = D13084

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = NTC-201-6A, revakinagene taroretcel-lwey

| IUPAC_name =

| chemical_formula_ref =

| chemical_formula =

| C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I=

| K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge=

| molecular_weight =

| molecular_weight_comment =

| SMILES =

| StdInChI =

| StdInChI_comment =

| StdInChIKey =

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Revakinagene taroretcel, sold under the brand name Encelto, is an allogeneic encapsulated cell-based gene therapy used for the treatment of macular telangiectasia type 2.{{cite journal | vauthors = Rim MH, Dean C, Aliaj E, Karas BL, Barada F, Levitsky AM | title = Recent and anticipated novel drug approvals (3Q 2024 through 2Q 2025) | journal = American Journal of Health-System Pharmacy | volume = 81 | issue = 22 | pages = 1103–1108 | date = November 2024 | pmid = 39194065 | doi = 10.1093/ajhp/zxae242 }} Revakinagene taroretcel is administered into the recipient's eye during a single surgical procedure.{{cite web | title=FDA Roundup: March 7, 2025 | website=U.S. Food and Drug Administration | date=7 March 2025 | url=https://www.fda.gov/news-events/press-announcements/fda-roundup-march-7-2025 | archive-url=https://web.archive.org/web/20250307232529/https://www.fda.gov/news-events/press-announcements/fda-roundup-march-7-2025 | url-status=dead | archive-date=7 March 2025 | access-date=7 March 2025}} {{PD-notice}}

Revakinagene taroretcel works by expressing recombinant human ciliary neurotrophic factor, which is a factor that may promote the survival and maintenance of the macular photoreceptors.

Revakinagene taroretcel was approved for medical use in the United States in March 2025.{{cite web | title=Encelto | website=U.S. Food and Drug Administration | date=1 October 2024 | url=https://www.fda.gov/vaccines-blood-biologics/center-biologics-evaluation-and-research-cber-product-approval-information/encelto | archive-url=https://web.archive.org/web/20250307223027/https://www.fda.gov/vaccines-blood-biologics/center-biologics-evaluation-and-research-cber-product-approval-information/encelto | url-status=dead | archive-date=7 March 2025 | access-date=7 March 2025}}